stockrowZevra Therapeutics, Inc.
ZVRA Healthcare Biotechnology
Zevra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.5 million, up 350.9% from fiscal 2024.
- Revenue
- +44.9%
- EPS
- +3,333.0%
- Free cash flow
- +106.8%
- Total debt
- +4.07%
Quarter to September 2026, against a year earlier
Follow ZVRA
Alert me
Zevra Therapeutics, Inc. (ZVRA) EV/Sales
As of 6 November 2026, Zevra Therapeutics, Inc. (ZVRA) trades at a EV/Sales of 4.0×. Over the past ten years it has ranged from 0.0× (June 2020) to 19.2× (December 2024); the current reading is higher than 54% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.8× | (78.32%) |
| FY2024 | 17.5× | 121.43% |
| FY2023 | 7.9× | (7.29%) |
| FY2022 | 8.5× | 64.53% |
| FY2021 | 5.2× | (36.63%) |
| FY2020 | 8.2× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 3.8× | (29.54%) |
| Jun 2026 | 5.3× | 47.24% |
| Mar 2026 | 3.6× | (4.50%) |
| Dec 2025 | 3.8× | (25.77%) |
| 25 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HELP Cybin Inc. compare | n/m |
| SGMT Sagimet Biosciences Inc. compare | n/m |
| GERN Geron Corporation compare | 2.6× |
| WVE WAVE Life Sciences Ltd. compare | 3.6× |
| ZVRA Zevra Therapeutics, Inc. | 4.0× |
| FDMT 4D Molecular Therapeutics, Inc. compare | 5.7× |
| DBVT DBV Technologies S.A. compare | 211× |
| DSGN Design Therapeutics, Inc. compare | 1,919× |
| CADL Candel Therapeutics, Inc. compare | 3,940× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)